Read by QxMD icon Read

Lymphoma & leukemia

C Spilleboudt, Ph Thibaut, E Varlet, D Bron
Leukocytosis or an increase of white blood cells in the peripheral blood is a frequent anomaly. It is important to immediately distinguish if it is a benign or malignant leukocytosis and the analysis of the blood formula is the first step. The presence of abnormal cells such as blast cells is an alarm which must immediately consider the diagnosis of leukemia, and medullogram has to be performed. The presence of lymphoma cells will lead to the conclusion of lymphoproliferative disorder and the presence of myeloid precursors to a myeloproliferative disorder...
2018: Revue Médicale de Bruxelles
Anna Uri, Fred Lühder, Thomas Kerkau, Niklas Beyersdorf
Donor lymphocyte infusions (DLI) together with allogeneic hematopoietic stem cell transplantation (allo-HSCT) are routinely used as second-line treatment for hematological malignancies. Mature T cells in the graft crucially mediate a Graft versus Leukemia (GvL) response, but also attack healthy tissues in the recipient leading to potentially life-threatening acute Graft versus Host Disease (aGvHD). Using inducible CD28 knock-out C57BL/6 mice as T cell donors we have now assessed whether CD28 costimulation of donor CD4+ and/ or CD8+ T cells is required for an efficient GvL effect after allogeneic T cell transplantation into BALB/c recipients...
October 15, 2018: European Journal of Immunology
Ran Wu, Hui Yang, Jiangbo Wan, Xiaohui Deng, Linjun Chen, Siguo Hao, Liyuan Ma
Leukemia and lymphoma are common hematological malignancies in children and young adults, which pose a tremendous threat to the survival of these young patients worldwide, despite availability of various effective treatments. The Hippo pathway is a novel‑signaling pathway that regulates organ size, cell proliferation, apoptosis and tumorigenesis. The chief component of this pathway is the transducer yes‑associated protein (YAP) which is over‑expressed in numerous categories of tumors. However, little is known about the effect of YAP in hematological malignancies...
October 15, 2018: Molecular Medicine Reports
Jing Li, Chang-Kui Sun
microRNA (miRNA)‑26a‑loaded liposomes were prepared in the present study for effective treatment of leukemia. The results demonstrated that miRNA‑26a reduced the viability of chronic lymphocytic leukemia (CLL) cells in a concentration‑dependent manner. Cells treated with miRNA‑26a‑loaded liposomes exhibited increased rates of apoptosis, as determined by flow cytometry and Hoechst 33342 staining. Western blot analysis revealed an increased apoptotic effect of miRNA‑26a‑loaded liposomes compared with control...
October 10, 2018: International Journal of Molecular Medicine
Jae Yoon Park, Wei Guo, Mohammed Al-Hijji, Abdallah El Sabbagh, Kebede H Begna, Thomas M Habermann, Thomas E Witzig, Bradley R Lewis, Amir Lerman, Joerg Herrmann
BACKGROUND: Cancer and cardiovascular diseases are the two leading causes of death in industrialized countries. Optimal management of life-threatening presentations of both of their diseases can pose significant challenges. The current study aimed to address the incidence, management, and outcome of acute coronary syndromes (ACS) in patients with active hematological malignancies. METHODS: This retrospective registry-based cohort study included adults with active leukemia or lymphoma who were hospitalized at Mayo Clinic Rochester from 01/01/2004 to 12/31/2014...
October 5, 2018: International Journal of Cardiology
J Rao, M Ruan, B H Yu, X Q Li, W T Yang, R H Shui
Objective: To investigate the clinicopathologic features and differential diagnosis of breast lymphoma in core needle biopsy. Methods: Seventy-two cases of breast lymphoma in core needle biopsy between 2011 and 2016 were extracted from the pathology database of Fudan University Shanghai Cancer Center. The clinicopathologic features were analyzed. The histological diagnosis of the tumors was based on the WHO classifications of tumors of hematopoietic and lymphoid tissues. Immunohistochemistry and molecular methods were performed to detect related antigens and genes...
October 8, 2018: Zhonghua Bing Li Xue za Zhi Chinese Journal of Pathology
Walaa Hassan Nazmy, Eman Abdelmonem Elbassuoni, Fatma Farrag Ali, Rehab Ahmed Rifaai
Diabetes mellitus (DM) is closely associated with male infertility and sexual dysfunction. Recent data indicate that the proinsulin C-peptide (CP) exerts important physiological effects and shows the characteristics of an endogenous peptide hormone. So, this study was done to investigate the effect of C-peptide with or without insulin treatment on testicular function and architecture in diabetic rats. Rats were divided into the following groups: control, diabetic, and diabetic groups treated with either CP alone or combined with insulin...
October 14, 2018: Journal of Cellular Physiology
Paola Ghione, Alison J Moskowitz, Nadia E K De Paola, Steven M Horwitz, Marco Ruella
PURPOSE OF REVIEW: Novel immunotherapies such as checkpoint inhibitors, bispecific antibodies, and chimeric antigen receptor T cells are leading to promising responses when treating solid tumors and hematological malignancies. T cell neoplasms include leukemia and lymphomas that are derived from T cells and overall are characterized by poor clinical outcomes. This review describes the rational and preliminary results of immunotherapy for patients with T cell lymphoma and leukemia. RECENT FINDINGS: For T cell neoplasms, despite significant research effort, only few agents, such as monoclonal antibodies and allogeneic stem cell transplantation, showed some clinical activity...
October 13, 2018: Current Hematologic Malignancy Reports
Hanna Grauers Wiktorin, Malin S Nilsson, Roberta Kiffin, Frida Ewald Sander, Brianna Lenox, Anna Rydström, Kristoffer Hellstrand, Anna Martner
Myeloid-derived suppressor cells (MDSCs) are immature monocytes and granulocytes that impede immune-mediated clearance of malignant cells by multiple mechanisms, including the formation of immunosuppressive reactive oxygen species (ROS) via the myeloid cell NADPH oxidase (NOX2). Histamine dihydrochloride (HDC), a NOX2 inhibitor, exerts anti-cancer efficacy in experimental tumor models but the detailed mechanisms are insufficiently understood. To determine effects of HDC on the MDSC compartment we utilized three murine cancer models known to entail accumulation of MDSC, i...
October 12, 2018: Cancer Immunology, Immunotherapy: CII
G Fraser, P Cramer, F Demirkan, R Santucci Silva, S Grosicki, A Pristupa, A Janssens, J Mayer, N L Bartlett, M-S Dilhuydy, H Pylypenko, J Loscertales, A Avigdor, S Rule, D Villa, O Samoilova, P Panagiotidis, A Goy, M A Pavlovsky, C Karlsson, M Hallek, M Mahler, M Salman, S Sun, C Phelps, S Balasubramanian, A Howes, A Chanan-Khan
We report follow-up results from the randomized, placebo-controlled, phase 3 HELIOS trial of ibrutinib+bendamustine and rituximab (BR) for previously treated chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) without deletion 17p. Overall, 578 patients were randomized 1:1 to either ibrutinib (420 mg daily) or placebo, in combination with 6 cycles of BR, followed by ibrutinib or placebo alone. Median follow-up was 34.8 months (range: 0.1-45.8). Investigator-assessed median progression-free survival (PFS) was not reached for ibrutinib+BR, versus 14...
October 12, 2018: Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K
David M Ross, Ilaria S Pagani, Naranie Shanmuganathan, Chung H Kok, John F Seymour, Anthony K Mills, Robin J Filshie, Christopher K Arthur, Phuong Dang, Verity A Saunders, Jodi Braley, Agnes S Yong, David T Yeung, Deborah L White, Andrew P Grigg, Anthony P Schwarer, Susan Branford, Timothy P Hughes
Following the achievement of deep molecular response on tyrosine kinase inhibitors (TKIs), approximately half of patients with chronic myeloid leukemia (CML) can discontinue TKI and remain in treatment-free remission (TFR). The ALLG CML8 study enrolled 40 imatinib-treated patients with undetectable BCR-ABL1 mRNA (approximately MR4.5 ). Molecular relapse was defined as detectable BCR-ABL1 on two consecutive tests or any single value >0.1%. With a median follow-up of 8.6 years (range 5.7-11.2 years), 18 patients remain in continuous TFR (45...
October 12, 2018: Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K
Hermenegildo González García, Rebeca Garrote Molpeceres, Elena Urbaneja Rodríguez, Pilar Gutiérrez Meléndez, Raquel Herráiz Cristóbal, María Asunción Pino Vázquez
The aim of this study is to describe childhood cancer incidence and survival in Castilla y León (Spain) for the period 2003 to 2014 and to explore differences between rural and urban areas.We made a cohort study in the childhood population of our region for the period of years referred before. Age-adjusted incidence rates to the world standard population (ASRw) were calculated by direct method, and their comparisons were made using incidence rate rations. Survival proportions were calculated by Kaplan-Meier method and their comparisons with log-rank test...
October 2018: Medicine (Baltimore)
Ping Wang, Xian'gui Peng, Xiaojuan Deng, Li Gao, Xi Zhang, Yimei Feng
RATIONALE: The diagnosis of hematological malignancies depends on laboratory analysis and often requires multiple experimental methods to judge, otherwise misdiagnosis is apt to happen. Lymph node biopsy immunohistochemistry (IHC) for T-lymphoblastic lymphoma (T-LBL) requires the establishment of antibody set screening. For identifying T-LBL and early T-cell precursor acute lymphoblastic leukemia (ETP-ALL) by lymph node biopsy and IHC, WHO has not yet proposed a better IHC antibody combination...
October 2018: Medicine (Baltimore)
Liye Xu, Jin Cheng Song, Xiu Hua Sun, Zi Fen Gao, Li Lv, Jie Zhu
RATIONALE: Central nervous system (CNS) infiltration of Richter's syndrome (RS) is rare and only a few cases were discussed. Of these published cases, either they were accompanied with lymph node involvement or with a history of chronic lymphocytic leukemia (CLL). To our knowledge, this is the first published case of RS of the brain and meninges diagnosed concurrently with CLL in the absence of any evidence of lymphoma outside of the CNS. PATIENT CONCERNS: A 67-year-old female presented with slurred speech, headache, and left-sided hemiparesis...
October 2018: Medicine (Baltimore)
Pingyuan Wang, Jia Zhou
Great success has been achieved in small molecule drug discovery programs, making extraordinary contributions for human health, especially in targeted therapy. Taking anticancer drug discovery as an example, small molecules traditionally inhibit the target protein enzyme activities and induce cancer cell apoptosis through the target binding. However, the target protein within tumor cells often recovers its activities, leading to acquired drug-resistance through the overexpression of the target protein or the generation of new mutations in the target protein [1]...
October 9, 2018: Current Topics in Medicinal Chemistry
Masahiro Sekimizu
Hematological malignancies (HM) comprise the major proportion of the cancer incidence and mortality in the adolescent and young adult (AYA) age group. Even though age-related differences in tumor biology have been reported in HM, further biological studies are warranted for elucidating age-related differences in AYAs. Hemato-oncologists and pediatric oncologists frequently follow various treatment strategies for HM, as the treatment strategy that is more suitable for this age group remains unclear. Recently, the involvement of pediatric oncologists has increased because the advantage of pediatric-type treatment has been demonstrated in acute lymphoblastic leukemia (ALL) and the significance of long-term follow-up has been clarified...
2018: [Rinshō Ketsueki] the Japanese Journal of Clinical Hematology
Naoki Hosen
CAR T-cell therapy is a novel cancer immunotherapy targeting cancer-specific cell-surface antigen. CD19-CAR T cells have been demonstrated to be highly efficacious in treating B-cell leukemia/lymphoma. Currently, several researchers are developing CAR T cells for multiple myeloma. In some early-phase clinical trials, CAR T cells targeting B-cell maturation antigen have exhibited promising efficacy. Recently, we reported that CAR T cells targeting the activated integrin 7 can selectively eradicate MM cells including CD19+ clonotypic B cells; a clinical trial for further assessment regarding this study is in process...
2018: [Rinshō Ketsueki] the Japanese Journal of Clinical Hematology
Takashi Ishida
Patients with adult T-cell leukemia/lymphoma (ATL), which is caused by human T-cell lymphotropic virus type 1, exhibit an extremely poor prognosis. ATL was first reported in 1977 in Japan as a distinct T-cell neoplasm, and its basic and clinical research have been led by Japanese investigators. This study aims to review the scenario since the discovery of ATL/HTLV-1 to the current status of ATL research and medicine and to consider its future directions.
2018: [Rinshō Ketsueki] the Japanese Journal of Clinical Hematology
Yasunori Kogure, Keisuke Kataoka
Adult T-cell leukemia/lymphoma (ATL) is a peripheral T-cell neoplasm with a dismal prognosis. This disease is caused by human T-cell leukemia virus type-1 (HTLV-1) retrovirus. Not only viral proteins, such as Tax and HBZ, but also additional genetic and epigenetic aberrations, including gain-of-function alterations in the components of T-cell receptor/NF-κB pathway or deteriorating alterations responsible for immune surveillance, are essential for ATL development and progression. Furthermore, recent investigation has demonstrated the effects of genetic and epigenetic alterations prevalently identified in ATL on the disease phenotype and its clinical outcomes...
2018: [Rinshō Ketsueki] the Japanese Journal of Clinical Hematology
Kritika Subramanian, Tim Dierckx, Ricardo Khouri, Soraya Maria Menezes, Huseini Kagdi, Graham P Taylor, Lourdes Farre, Achilea Bittencourt, Keisuke Kataoka, Seishi Ogawa, Johan Van Weyenbergh
Retinoic acid-related drugs have shown promising pre-clinical activity in Adult T-cell Leukemia/Lymphoma, but RORC signaling has not been explored. Therefore, we investigated transcriptome-wide interactions of the RORC pathway in HTLV-1 and ATL, using our own and publicly available gene expression data for ATL and other leukemias. Gene expression data from ATL patients were analyzed using WGCNA to determine gene modules and their correlation to clinical and molecular data. Both PBMCs and CD4+ T-cells showed decreased RORC expression in four different ATL cohorts...
October 10, 2018: International Journal of Cancer. Journal International du Cancer
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"